Will 14-3-3η Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment

Abstract

Aim of the Work. To evaluate diagnostic and prognostic capacity of 14-3-3η protein in early RA, investigate its pathogenic and theragnostic role, and find its correlations with disease activity and severity in established RA patients. Subjects and Methods: 80 patients with early RA, 80 patients with established RA, and 80 healthy controls were included in this study. ROC curve analysis of RF, ACCP, and 14-3-3η in early disease was conducted, and serum levels of 14-3-3η were assessed by ELISA and reassessed in early RA patients 6 months after anti-TNF therapy. Correlation of 14-3-3η with parameters of disease activity and severity was analyzed. Results. Serum14-3-3η levels were significantly higher in all RA patients than in controls P < 0.001 , its sensitivity was 86.7% and 88.3% in early and established RA patients with a significant difference with RF and ACCP at early disease, and the specificity was 96.7%. There was a significant reduction of 14-3-3η levels 6 months after treatment in the first group p = 0.004 , and there was a significant positive correlation between serum 14-3-3η levels and parameters of disease activity and severity. Conclusion. 14-3-3η could be a novel, potent, and efficacious diagnostic, and prognostic marker for RA with high sensitivity, that may become a new therapeutic target for RA.

The Diagnostic Significance of Serum Sclerostin in Early Detection of Rheumatoid Arthritis in Syrian Patients

“…The study by El-Bakry et al showed that serum sclerostin levels of 267ng/dl, a sensitivity of 96.8%, and a specificity of 66.7% [31] were recorded. In the study by Shawky Alashkar in 2022 conducted on 80 early patients, the sensitivity and specificity of anti-CCP were 68.3%, 95%, and 61.7%, 88.3% for RF antibodies, respectively [35]. The 2019 study by Singh et al in India demonstrated that at a value of 394 pg/ml, the sensitivity was 100%, the specificity was 90%, PPV was 90%, and NPV was 100% to differentiate the group of rheumatoid arthritis patients from the healthy group [24].…”

Serum 14-3-3 ETA levels in ankylosing spondylitis with pure axial involvement: Could it be a potential biomarker to assess disease activity?

“…In the literature, a relationship has been shown between disease activity and disease progression and the levels of eta in patients with RA (13,21). 14-3-3η has been detected in the serum and more specifically in the synovial fluid of patients with RA, and it is a valuable marker for the diagnosis of patients and also indicates the severity of the disease and joint destruction (13,(22)(23)(24).…”

The Association of Serum RANKL Levels with disease activity and Hematological Parameters in Syrian Patients with Rheumatoid Arthritis

“…About (33%) of RA patients are ACPA-seronegative 1 and 30% to 45% are RF seronegative despite the appearance of symptoms 9 . The sensitivity of ACPA and RF in established RA range from 56-80% and 60 to 86% respectively 1,12 . While for early RA, the sensitivity of RF is 57% and its low specificity ranges between 70-85% 12 .…”

“…The sensitivity of ACPA and RF in established RA range from 56-80% and 60 to 86% respectively 1,12 . While for early RA, the sensitivity of RF is 57% and its low specificity ranges between 70-85% 12 . On the other hand, it is estimated that about 70% of joints may be destroyed during the second year of disease onset 2 .…”